sr141716 has been researched along with Bone Diseases, Metabolic in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Chen, Y; Dou, ZJ; Gao, XL; Jia, YL; Liu, T; Wang, B; Wang, MT; Wu, SJ; Yang, C; Yang, JJ; Zhang, N | 1 |
1 other study(ies) available for sr141716 and Bone Diseases, Metabolic
| Article | Year |
|---|---|
CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced bone metabolism disorder and destruction in rats.
Topics: Animals; Bone Diseases, Metabolic; Cannabinoid Receptor Antagonists; Disease Models, Animal; Hypoxia; Male; Osteoclasts; Protective Agents; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Tartrate-Resistant Acid Phosphatase | 2020 |